Regeneron's Eylea HD wins FDA nod for 5-month dosing interval

Regeneron Pharmaceuticals Inc. received U.S. Food and Drug Administration approval for its high-dose aflibercept injection, EYLEA HD, for treating wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) at dosing intervals of up to 5 months.

The approval on April 2, 2026, was based on 96-week results from the pivotal PULSAR and PHOTON clinical trials, which involved patients with wAMD and DME, respectively. The data showed EYLEA HD offers comparable vision gains to the standard 2 mg EYLEA dose but with less frequent injections.

In the two pivotal trials, EYLEA HD demonstrated non-inferiority in best corrected visual acuity (BCVA) gains at 48 weeks compared to the standard EYLEA injection. A majority of patients maintained these visual and anatomic improvements with extended dosing intervals of 12 or 16 weeks at the 96-week mark.

The less frequent dosing schedule is a significant development for patients, reducing the treatment burden associated with frequent eye injections. The approval strengthens Regeneron's competitive position in the ophthalmology market, creating new pressure on existing treatments, including Roche's Vabysmo, which also offers extended dosing.

The approval is expected to be a significant growth driver for Regeneron, potentially boosting its stock price and increasing its market share in the estimated $12 billion global market for retinal disease therapies. The ability to extend dosing to every 4 or even 5 months for some patients addresses a major unmet need for this patient population.

This approval solidifies Regeneron's franchise in the anti-VEGF market by providing a more convenient and effective treatment option. Investors will closely watch initial sales figures in the upcoming quarters to assess the market's adoption of EYLEA HD against its primary competitor, Vabysmo.

This article is for informational purposes only and does not constitute investment advice.